An interventional study of omega-3 and placebo in Depression, sponsored by Nanfang Hospital, Southern Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Nanfang Hospital, Southern Medical University · Not applicable, Interventional, and Treatment
Depression is a serious mental illness, with persistent depression and loss of interest as the main clinical manifestations, and causes varying degrees of cognitive impairment, further leading to impaired social function, and even lead to suicidal behavior. Previous studies on the antidepressant effects of Omega-3 mainly focused on chronic effects, and there was a lack of corresponding rapid response clinical studies. Because of the nature of Omega-3 health products, no clinical adverse effects have been reported. We have previously shown that Omega-3 can produce antidepressant and cognitive improvement effects. This study will carry out different doses (low dose and high dose) and single active ingredient (EPA alone) to observe the antidepressant and cognitive improvement effects of Omega-3 in clinical patients with major depression. The antidepressant effect and cognitive improvement effect of Omega-3 will be further verified to provide evidence for future clinical application.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's planned enrollment of 64 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A single dose of 4.0g EPA was given orally
Dietary Supplement: omega-3
A single dose of 2.0g EPA was given orally
Dietary Supplement: omega-3
A single dose of 4.0g corn oil was given orally
Dietary Supplement: placebo
no intervention. assessement of cognitive performance twice.
supplement in the market
corn oil
depressive symptom
Hamilton Depression Scale (HAMD)-17, more reduaction mean better outcome
Time frame: 40 minutes
Cognitive performance Working memory
Working memory: digit span test from the Wechsler Memory Scale-Third Edition (WMS-III)
Time frame: 4 hours
Cognitive performance Verbal memory
Verbal memory: evaluate the Logical Memory including immediate/delayed recall and recognition from the WMS-III.
Time frame: 4 hours
Cognitive performance Visual memory
Visual memory: Rey-Osterrieth Complex Figure (ROCF) task
Time frame: 4 hours
Cognitive performance
executive function: the Stroop Test and the Wisconsin Card Sorting Test (WCST). more improvement mean better outcome
Time frame: 4 hours
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University